Advertisement

Tumor Biology

, Volume 37, Issue 6, pp 8337–8347 | Cite as

Genetic variants in EBV reactivation-related genes and the risk and survival of breast cancer

  • Wei Zhang
  • Zheng-Zheng Zhang
  • Lu-Ying Tang
  • Ying Lin
  • Feng-Xi Su
  • Xiao-Ming Xie
  • Xue-Fen Su
  • Ze-Fang Ren
Original Article

Abstract

Tumor susceptibility gene 101 (TSG101) and activating transcription factor 2 (ATF2) have been suggested to involve in the reactivation of EBV which has implications in the development and progression of breast cancer. Therefore, the polymorphisms of TSG101 and ATF2 may associate with breast cancer risk and prognosis. A case-control study with 1551 breast cancer cases and 1605 age-matched controls were conducted in Guangzhou, China. We have also successfully followed up 1168 cases until December 31, 2014. The variant allele of TSG101 rs2292179 was associated with a non-significant reduced risk of breast cancer, particularly among women with BMI < 24 (kg/m2) (P for interaction <0.05). For ATF2 rs3845744, the variant allele was also associated with a significantly reduced breast cancer risk [odds ratio (OR) (95 % confidence interval (CI)) 0.86 (0.74∼1.00)], and the association occurred among only postmenopausal women [OR (95 % CI) 0.69 (0.54∼0.88)] (P for interaction <0.05). Breast cancer risk was further reduced with the increasing numbers of the variant G alleles of the two polymorphisms (P for trend <0.05). We did not find an overall association of the two loci with breast cancer prognosis, while the hazard ratios of the two loci (AG/GG vs. AA) were significantly higher among postmenopausal women than premenopausal women (P = 0.046, 0.016 for TSG101 rs2292179 and ATF2 rs3845744, respectively). In summary, the variant alleles of TSG101 rs2292179 and ATF2 rs3845744 were associated with a reduced risk of breast cancer, particularly for subjects with BMI <24 (kg/m2) and postmenopausal women, respectively. The two SNPs and menopausal status may have a significant interaction on breast cancer progression.

Keywords

TSG101 ATF2 Polymorphisms Prognosis Breast cancer 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grant number: 81273147). The authors would like to thank all the study participants and nursing and administrative staff in the Breast Departments of The First and Second Affiliated Hospitals and Cancer Center, Sun Yat-sen University.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Young LS, Rickinson AB. Epstein–Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757–68.CrossRefPubMedGoogle Scholar
  2. 2.
    He JR, Tang LY, Yu DD, Su FX, Song EW, Lin Y, et al. Epstein-Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma. Cancer Lett. 2011;309:128–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Hippocrate A, Oussaief L, Joab I. Possible role of EBV in breast cancer and other unusually EBV-associated cancers. Cancer Lett. 2011;305:144–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Richardson AK, Currie MJ, Robinson BA, Morrin H, Phung Y, Pearson JF, et al. Cytomegalovirus and Epstein-Barr virus in breast cancer. PLoS One. 2015;10:e118989.Google Scholar
  5. 5.
    Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10:803–21.CrossRefPubMedGoogle Scholar
  6. 6.
    De-The G, Day NE, Geser A, Lavoue MF, Ho JH, Simons MJ, Sohier R, Tukei P, Vonka V, Zavadova H: Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study—a review. IARC Sci Publ 1975:3-16Google Scholar
  7. 7.
    Fang CY, Huang SY, Wu CC, Hsu HY, Chou SP, Tsai CH, et al. The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cells. PLoS One. 2012;7:e44810.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fachiroh J, Prasetyanti PR, Paramita DK, Prasetyawati AT, Anggrahini DW, Haryana SM, et al. Dried-blood sampling for Epstein-Barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening. J Clin Microbiol. 2008;46:1374–80.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chua HH, Lee HH, Chang SS, Lu CC, Yeh TH, Hsu TY, et al. Role of the TSG101 gene in Epstein-Barr virus late gene transcription. J Virol. 2007;81:2459–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J, et al. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol. 2000;74:1224–33.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Darr CD, Mauser A, Kenney S. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol. 2001;75:6135–42.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lo YF, Chen TC, Chen SC, Chao CC. Aberrant expression of TSG101 in Taiwan Chinese breast cancer. Breast Cancer Res Treat. 2000;60:259–66.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang Y, Song M, Cui ZS. Down-regulation of TSG101 by small interfering RNA inhibits the proliferation of breast cancer cells through the MAPKERK signal pathway. Histol Histopathol. 2011;26:87–94.PubMedGoogle Scholar
  14. 14.
    Woo IS, Kohno T, Inoue K, Ishii S, Yokota J. Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer. Int J Oncol. 2002;20:527–31.PubMedGoogle Scholar
  15. 15.
    Bhoumik A, Ronai Z. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle. 2008;7:2341–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Maekawa T, Shinagawa T, Sano Y, Sakuma T, Nomura S, Nagasaki K, et al. Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol. 2007;27:1730–44.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S, et al. ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene. 2008;27:1045–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Ren ZF, Liu WS, Qin HD, Xu YF, Yu DD, Feng QS, et al. Effect of family history of cancers and environmental factors on risk of nasopharyngeal carcinoma in Guangdong, China. Cancer Epidemiol. 2010;34:419–24.CrossRefPubMedGoogle Scholar
  19. 19.
    Rothman KJ. The estimation of synergy or antagonism. Am J Epidemiol. 1976;103:506–11.PubMedGoogle Scholar
  20. 20.
    Li L, Li X, Francke U, Cohen SN. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell. 1997;88:143–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee MP, Feinberg AP. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res. 1997;57:3131–4.PubMedGoogle Scholar
  22. 22.
    Sun Z, Pan J, Bubley G, Balk SP. Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene. 1997;15:3121–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Wang Q, Driouch K, Courtois S, Champeme MH, Bieche I, Treilleux I, et al. Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers. Oncogene. 1998;16:677–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Gayther SA, Barski P, Batley SJ, Li L, de Foy KA, Cohen SN, et al. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene. 1997;15:2119–26.CrossRefPubMedGoogle Scholar
  25. 25.
    Li L, Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell. 1996;85:319–29.CrossRefPubMedGoogle Scholar
  26. 26.
    Bleiber G, May M, Martinez R, Meylan P, Ott J, Beckmann JS, et al. Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. J Virol. 2005;79:12674–80.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, et al. Levels of circulating regulatory CD4 + CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat. 2006;98:17–29.CrossRefPubMedGoogle Scholar
  28. 28.
    Young TW, Mei FC, Rosen DG, Yang G, Li N, Liu J, et al. Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. Mol Cell Proteomics. 2007;6:294–304.CrossRefPubMedGoogle Scholar
  29. 29.
    Krishnan J, Danzer C, Simka T, Ukropec J, Walter KM, Kumpf S, et al. Dietary obesity-associated Hif1 activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Gene Dev. 2012;26:259–70.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Benedetto C, Salvagno F, Canuto EM, Gennarelli G. Obesity and female malignancies. Best Pract Res Clin Obstet Gynaecol. 2015;29:528–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Lopez-Bergami P, Lau E, Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer. 2010;10:65–76.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Song H, Ki SH, Kim SG, Moon A. Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells. Cancer Res. 2006;66:10487–96.CrossRefPubMedGoogle Scholar
  33. 33.
    Kim ES, Sohn YW, Moon A. TGF-beta-induced transcriptional activation of MMP-2 is mediated by activating transcription factor (ATF)2 in human breast epithelial cells. Cancer Lett. 2007;252:147–56.CrossRefPubMedGoogle Scholar
  34. 34.
    Lin TY, Chu YY, Yang YC, Hsu SW, Liu ST, Chang LK. MCAF1 and Rta-activated BZLF1 transcription in Epstein-Barr virus. PLoS One. 2014;9:e90698.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Su B, Tang HL, Deng M, Liao QJ, Zeng X, Zhang WL, et al. Stage-associated dynamic activity profile of transcription factors in nasopharyngeal carcinoma progression based on protein/DNA array analysis. OMICS. 2011;15:49–60.CrossRefPubMedGoogle Scholar
  36. 36.
    Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, Gorgoulis V, Zoumpourlis V. The role of ATF-2 in oncogenesis. BioEssays. 2008;30:314–27.CrossRefPubMedGoogle Scholar
  37. 37.
    Lewis JS. Differential effects of 16-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. J Mol Endocrinol. 2005;34:91–105.CrossRefPubMedGoogle Scholar
  38. 38.
    Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996;69:92–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Jorgensen TJ, Ruczinski I, Kessing B, Smith MW, Shugart YY, Alberg AJ. Hypothesis-driven candidate gene association studies: practical design and analytical considerations. Am J Epidemiol. 2009;170:986–93.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Wei Zhang
    • 1
  • Zheng-Zheng Zhang
    • 1
    • 2
  • Lu-Ying Tang
    • 3
  • Ying Lin
    • 4
  • Feng-Xi Su
    • 5
  • Xiao-Ming Xie
    • 6
  • Xue-Fen Su
    • 7
  • Ze-Fang Ren
    • 1
    • 8
  1. 1.The School of Public Health, Sun Yat-sen UniversityGuangzhouChina
  2. 2.Aviation Hygiene Management DivisionChina Southern Airlines Company LimitedGuangzhouChina
  3. 3.The Third Affiliated HospitalSun Yat-sen UniversityGuangzhouChina
  4. 4.The First Affiliated HospitalSun Yat-sen UniversityGuangzhouChina
  5. 5.The Second Affiliated HospitalSun Yat-sen UniversityGuangzhouChina
  6. 6.The Sun Yat-Sen University Cancer CenterGuangzhouChina
  7. 7.School of Public Health and Primary Care, Faculty of MedicineThe Chinese University of Hong KongHong KongChina
  8. 8.Department of Statistics and Epidemiology, Guangzhou Key Laboratory of Environmental Pollution and Health Risk Assessment, School of Public HealthSun Yat-sen UniversityGuangzhouChina

Personalised recommendations